公开(公告)号：WO2008127317A3

公开(公告)日：2008-10-23

申请号：PCT/US2007/024543

申请日：2007-11-29

Applicant: ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE ,  POTASHKIN, Judith, Ann

Inventor： POTASHKIN, Judith, Ann

IPC: C12P19/34 ,  C07H21/02

Abstract: The present invention discloses a method to discover biomarkers indicative of an idiopathic neurodegenerative disease in a mammalian subject and biomarkers indicative of an idiopathic neurodegenerative disease in the mammalian subject. The biomarker comprises a splice variant mRNA of a precursor-messenger RNA (pre-mRNA) transcript of a gene in the mammalian subject wherein (a) the ratio of the amount of the splice variant mRNA to the amount of another splice variant mRNA of the same precursor-messenger RNA (pre-mRNA) transcript of the same gene is different in the mammalian subject having the neurodegenerative disease as compared to that of a control without the disease; or (b) the ratio of the amount of the splice variant mRNA to the amount of total 18S RNA is different in the mammalian subject having the neurodegenerative disease as compared to that of a control without the disease. The biomarkers can be used to diagnose neurodegenerative diseases in the subject.

公开(公告)号：WO2007005990A2

公开(公告)日：2007-01-11

申请号：PCT/US2006/026257

申请日：2006-06-30

Applicant: ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE ,  PETERSON, Darryl, R.

Inventor： PETERSON, Darryl, R.

IPC: A61K38/17

CPC classification number: A61K38/05 ,  A61K38/49

Abstract: The present invention relates generally to the use of γ-glutamyl antioxidants, particularly γ-glutamyl-cysteine, as cytoprotective agents to prevent reperfusion injury (i.e., hemorrhagic transformation) of the blood-brain barrier during reperfusion following an ischemic stroke. The γ-glutamyl antioxidants can be used alone or used in combination with an agent which inhibits the reverse movement of Na/Ca exchange in the blood-brain barrier such as 2-[2-[4-(4-nitrobenzyloxy)phenyl]ethyl]isothiourea methanesulphonate (KB-R7943).

Abstract translation: 本发明一般涉及γ-谷氨酰基抗氧化剂，特别是β-谷氨酰半胱氨酸作为细胞保护剂，以防止缺血性卒中后再灌注期间血脑屏障的再灌注损伤（即，出血性转化）。 α-谷氨酰基抗氧化剂可以单独使用或与抑制血脑屏障中Na / Ca交换反向移动的试剂组合使用，例如2- [2- [4-（4-硝基苄氧基）苯基]乙基 ]异硫脲甲磺酸盐（KB-R7943）。

公开(公告)号：WO2006074452A3

公开(公告)日：2006-07-13

申请号：PCT/US2006/000833

申请日：2006-01-10

Applicant: ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE ,  RISER, Bruce, L.

Inventor： RISER, Bruce, L. ,  PERBAL, Bernard

IPC: A01N37/18

Abstract: The present invention discloses a role of CCN3 in diseases associated with the overexpression of CCN2, which include but are not limited to kidney disease, fibrosis, and cancer. The full length CCN3 protein or fragments thereof or isoforms (or combinations) of CCN3 are involved in these diseases. The isolated and purified CCN3 protein or its fragments or isoforms (or combinations) of CCN3 can be potentially used in the treatment or prevention of these diseases by regulating the expression and/or activity of the CCN2 protein. The level of CCN3 in tissue or body fluids can also be used to predict, diagnose and/or follow the progression of diseases as well as to determine the effectiveness of therapeutic intervention.

公开(公告)号：WO2022011239A1

公开(公告)日：2022-01-13

申请号：PCT/US2021/041054

申请日：2021-07-09

Applicant: ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE ,  THE UNITED STATES AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (WASHINGTON, D.C.)

Inventor： GAZMURI, Raúl J. ,  RADHAKRISHNAN, Jeejabai ,  AIELLO, Salvatore

IPC: A61K31/7048 ,  A61K9/00 ,  A61P9/04

Abstract: A method of performing cardiopulmonary resuscitation on a mammalian subject including the step of delivering an effective amount of a gliflozin solution during cardiac resuscitation through an intravenous or intraosseous route.

公开(公告)号：WO2017087282A1

公开(公告)日：2017-05-26

申请号：PCT/US2016/061664

申请日：2016-11-11

Applicant: ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE ,  THE MCLEAN HOSPITAL CORPORATION

Inventor： HASTINGS, Michelle, L. ,  ISACSON, Ole ,  KORECKA-ROET, Joanna, A.

IPC: C12N15/113 ,  A61K31/712 ,  A61K31/7125 ,  C07H21/00 ,  A61P25/28

CPC classification number: C12N15/1137 ,  C12N2310/11 ,  C12N2310/315 ,  C12N2310/3231 ,  C12N2310/3233 ,  C12N2310/346 ,  C12N2320/33 ,  C12Y207/11001 ,  C12N2310/321 ,  C12N2310/3521 ,  C12N2310/3525 ,  C12N2310/322 ,  C12N2310/3533

Abstract: The present disclosure relates generally to compounds comprising oligonucleotides complementary to a Leucine-Rich-Repeat-Kinase (LRRK2) RNA transcript. Certain such compounds are useful for hybridizing to a LRRK2 RNA transcript, including but not limited to a LRRK2 RNA transcript in a cell. In certain embodiments, such hybridization results in modulation of splicing of the LRRK2 transcript. In certain embodiments, such compounds are used to treat one or more symptoms associated with Parkinson's disease.

Abstract translation: 本公开一般涉及包含与富亮氨酸重复激酶（LRRK2）RNA转录物互补的寡核苷酸的化合物。 某些此类化合物可用于与LRRK2RNA转录物杂交，包括但不限于细胞中的LRRK2RNA转录物。 在某些实施方案中，这种杂交导致调节LRRK2转录物的剪接。 在某些实施方案中，这些化合物用于治疗与帕金森氏病有关的一种或多种症状。

公开(公告)号：WO2016201214A1

公开(公告)日：2016-12-15

申请号：PCT/US2016/036872

申请日：2016-06-10

Applicant: STC. UNM ,  ROSALIND FRANKLIN UNIVERSITY

Inventor： OPREA, Tudor, I. ,  BOLOGA, Cristian, George ,  URSU, Oleg ,  CHOE, Jun-Yong ,  IANCU, Cristina

IPC: C07D317/48 ,  C07D319/08 ,  C07D321/10 ,  C07D405/12 ,  C07C309/46 ,  A61K31/357 ,  A61P3/00

CPC classification number: C07D317/66 ,  A23L33/125 ,  A23V2002/00 ,  A61K31/357 ,  A61K31/36 ,  A61K45/06 ,  C07C317/36 ,  C40B30/02

Abstract: The present invention relates to compounds which have been discovered to be potent ligands (inhibitors) of human GLUT5 (glucose transporter type 5), a facilitative glucose transporter that transports fructose, and their use as ligands assays which can uncover additional ligands of GLUT5, having the potential for being used as drugs. In addition, the present invention is directed to compounds, chemical compositions and methods for treating disease states and conditions which are mediated through GLUT5, including such disease states and conditions as GLUT5 deficiency syndrome, diabetes (type I and II), cancer, metabolic diseases including metabolic syndrome and fatty liver disease, among others.

Abstract translation: 本发明涉及已被发现是人GLUT5（葡萄糖转运体5型）的有效配体（抑制剂），促进果糖的促进性葡萄糖转运体及其作为配体测定法的用途的化合物，其可以揭示GLUT5的其它配体，其具有 被用作药物的潜力。 此外，本发明涉及用于治疗通过GLUT5介导的疾病状态和病症的化合物，化学组成和方法，包括GLUT5缺乏综合征，糖尿病（I型和II型），癌症，代谢疾病 包括代谢综合征和脂肪肝疾病等。

公开(公告)号：WO2016134021A1

公开(公告)日：2016-08-25

申请号：PCT/US2016/018275

申请日：2016-02-17

Applicant: ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE ,  HASTINGS, Michelle, L.

Inventor： HASTINGS, Michelle, L.

IPC: C12N15/113

CPC classification number: C12N15/1137 ,  C12N15/1138 ,  C12N2310/11 ,  C12N2310/315 ,  C12N2310/32 ,  C12N2310/321 ,  C12N2310/322 ,  C12N2310/3231 ,  C12N2310/3233 ,  C12N2310/351 ,  C12N2310/3521 ,  C12N2310/3525 ,  C12N2310/3533 ,  C12N2320/30 ,  C12N2320/33

Abstract: The present disclosure relates generally to compounds comprising oligonucleotides complementary to a cystic fibrosis transmembrane conductance regulator (CFTR) RNA transcript. Certain such compounds are useful for hybridizing to a CFTR RNA transcript, including but not limited to a CFTR RNA transcript in a cell. In certain embodiments, such hybridization results in modulation of splicing of the CFTR transcript. In certain embodiments, such compounds are used to treat one or more symptoms associated with Cystic Fibrosis.

Abstract translation: 本公开一般涉及包含与囊性纤维化跨膜传导调节子（CFTR）RNA转录物互补的寡核苷酸的化合物。 某些这样的化合物可用于与CFTR RNA转录物杂交，包括但不限于细胞中的CFTR RNA转录物。 在某些实施方案中，这种杂交导致调节CFTR转录物的剪接。 在某些实施方案中，这些化合物用于治疗与囊性纤维化相关的一种或多种症状。

公开(公告)号：WO2014176323A1

公开(公告)日：2014-10-30

申请号：PCT/US2014/035122

申请日：2014-04-23

Applicant: ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE

Inventor： BEAMAN, Kenneth

IPC: G01N33/53

CPC classification number: G01N33/689

Abstract: The present invention provides a kit for determining male fertility including a container system containing a plurality of enzyme-linked antibodies one of each capable of binding to analytes Atp6v0a2, G-CSF, MIP 1α, and MCP-1. The kit further includes suitable packaging and a set of instructions for using the enzyme-linked antibodies with a seminal sample to determine the fertility of the sample.

Abstract translation: 本发明提供了一种用于确定男性生殖力的试剂盒，其包括含有多个能够结合分析物Atp6v0a2，G-CSF，MIP1α和MCP-1的多个酶联抗体的容器系统。 试剂盒还包括合适的包装和一套使用酶联免疫抗体与精液样品来确定样品生育能力的说明书。

公开(公告)号：WO2011123858A2

公开(公告)日：2011-10-06

申请号：PCT/US2011/031121

申请日：2011-04-04

Applicant: ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE ,  RISER, Bruce

Inventor： RISER, Bruce

IPC: A61K35/12 ,  A61K38/10 ,  C07K7/08 ,  A61P9/10 ,  A61P35/00 ,  A61P19/08 ,  A61P43/00 ,  A61P9/00 ,  A61N1/30

CPC classification number: A61K38/10 ,  A61K38/08 ,  C07K14/4743 ,  C07K14/475

Abstract: The present invention provides a CCN3 mimic peptide for treating a subject in need thereof having an amino acid sequence identified as CCNp37, CCNp38 (human), CCNp38 (mouse), a cysteine-substituted CCNp37, cysteine-substituted CCNp38 (human) or a cysteine-substituted CCNp38 (mouse).

Abstract translation: 本发明提供了一种CCN3模拟肽，用于治疗有需要的受试者具有鉴定为CCNp37，CCNp38（人），CCNp38（小鼠），半胱氨酸取代的CCNp37，半胱氨酸取代的CCNp38（人）或半胱氨酸的氨基酸序列 - 取代的CCNp38（小鼠）。

公开(公告)号：WO2010037135A3

公开(公告)日：2010-07-22

申请号：PCT/US2009058883

申请日：2009-09-29

Applicant: UNIV CALIFORNIA ,  ROSALIND FRANKLIN UNIVERSITY O ,  MASLIAH ELIEZER ,  SPENCER BRIAN ,  ROCKENSTEIN EDWARD ,  MARR ROBERT

Inventor： MASLIAH ELIEZER ,  SPENCER BRIAN ,  ROCKENSTEIN EDWARD ,  MARR ROBERT

IPC: C07K19/00 ,  A61K38/00 ,  C07K14/47

CPC classification number: C07K14/4711 ,  A61K38/00 ,  C07K19/00

Abstract: The invention provides compositions for increasing the clearance of protein aggregates, and pharmaceutical compositions comprising them, and methods for making and using them, including methods for accelerating protein aggregate clearance in the CNS, e.g., for treating diseases that are characterized by protein aggregation - including some degenerative neurological diseases such as Parkinson's disease. In one aspect, the compositions of the invention specifically target synuclein, beta-amyloid and/or tau protein aggregates, and the methods of the invention can be used to specifically prevent, reverse, slow or inhibit synuclein, beta-amyloid and/or tau protein aggregation. In alternative embodiments, the compositions and methods of the invention, are used to treat, prevent, reverse (partially or completely) or ameliorate (including slowing the progression of) degenerative neurological diseases related to or caused by protein aggregation, e.g., synuclein, beta-amyloid and/or tau protein aggregation. In one aspect, compositions and methods of this invention are used to treat, prevent or ameliorate (including slowing the progression of) Parkinson's disease, fronto-temporal dementia (FTD), Alzheimer's Disease (AD), Lewy body disease (LBD) and Multiple system atrophy (MSA).

Abstract translation: 本发明提供了用于增加蛋白质聚集体清除率的组合物，以及包含它们的药物组合物，以及制备和使用它们的方法，包括加速CNS中蛋白质聚集体清除的方法，例如用于治疗以蛋白质聚集为特征的疾病 - 包括 一些退行性神经疾病如帕金森病。 在一个方面，本发明的组合物特异性靶向突触核蛋白，β-淀粉样蛋白和/或tau蛋白聚集体，并且本发明的方法可用于特异性预防，逆转，减缓或抑制突触核蛋白，β-淀粉样蛋白和/或tau 蛋白质聚集。 在可选的实施方案中，本发明的组合物和方法用于治疗，预防，逆转（部分或完全）或改善（包括减缓）与蛋白质聚集相关或由蛋白质聚集引起的退行性神经疾病，例如突触核蛋白，β - 淀粉样蛋白和/或tau蛋白聚集。 在一个方面，本发明的组合物和方法用于治疗，预防或改善帕金森病，额颞叶痴呆（FTD），阿尔茨海默病（AD），路易体病（LBD）和多发性 系统萎缩（MSA）。